Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas

Clinical Trial ID NCT01216839

PubWeight™ 4.02‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01216839

Top papers

Rank Title Journal Year PubWeight™‹?›
1 New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma. Cancer 2011 0.85
2 The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets. Biosci Rep 2014 0.83
3 Pediatric sarcomas: translating molecular pathogenesis of disease to novel therapeutic possibilities. Pediatr Res 2012 0.82
4 The importance of being dead: cell death mechanisms assessment in anti-sarcoma therapy. Front Oncol 2015 0.76
5 Advances in paediatric cancer treatment. Transl Pediatr 2014 0.76
Next 100